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Abstract
Members of the small GTPase family Rab are emerging as potentially important factors in cancer development and progression. A good number
of Rabs have been implicated or associated with various human cancers, and much recent excitement has been associated with the roles of the
Rab11 subfamily member Rab25 and its effector, the Rab coupling protein (RCP), in tumourigenesis and metastasis. In this review, we focus
on a Rab5 subfamily member, Rab31, and its implicated role in cancer. Well recognized as a breast cancer marker with good prognostic value,
recent findings have provided some insights as to the mechanism underlying Rab31’s influence on oncogenesis. Levels of Oestrogen Receptor
a (ERa)- responsive Rab31 could be elevated through stabilization of its transcript by the RNA binding protein HuR, or though activation by the
oncoprotein mucin1-C (MUC1-C), which forms a transcriptional complex with ERa. Elevated Rab31 stabilizes MUC1-C levels in an auto-induc-
tive loop that could lead to aberrant signalling and gene expression associated with cancer progression. Rab31 and its guanine nucleotide
exchange factor GAPex-5 have, however, also been shown to enhance early endosome-late endosome transport and degradation of the epider-
mal growth factor receptor (EGFR). The multifaceted action and influences of Rab31 in cancer is discussed in the light of its new interacting
partners and pathways.
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Introduction
There is an enormous flux of both membrane and soluble cargoes
between intracellular membranous compartments in the eukaryotic
cell. It is necessary for this flow of multidirectional traffic to be ade-
quately regulated, and dysregulation at any point of the trafficking
network could lead to disease states. A particularly important group
of proteins regulating membrane traffic in eukaryotic cells are the
Sar/Arf family and the Rab family of small GTPases [1]. Rabs (Ras-
related proteins in brain) [2, 3] constitute the largest subfamily of the
Ras superfamily of small GTPases [4], and has more than 60 genes
encoded within the human genome. Translated as soluble, cytosolic
proteins, Rabs acquire C-terminal prenylated lipid anchors (geranyl-
geranylation) and are localized rather specifically to different sub-cel-
lular compartments for the regulation of particular membrane
trafficking step(s) in the exocytic and endocytic pathways [5–7].
Analogous to the function of the proto-oncogene Ras in cellular
signalling [8], Rab proteins are post-translationally modified and go
through a cycle of guanine nucleotide exchange and hydrolysis to act
as key switches in membrane traffic pathways [2, 9]. Rabs are kept in
the cytosol by GDP dissociation inhibitors (GDIs) [10]. The Rab
escort protein engages cytosolic Rab proteins to be presented to Rab
geranylgeranyl transferase [11], allowing the Rab protein to be gera-
nylgeranylated at its C-terminal cysteine residues before it is escorted
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to the target membrane [12, 13]. The added lipid anchor facilitates
the attachment of a Rab protein to the target membrane, but full acti-
vation requires its bound GDP to be exchanged for GTP, a process
that is facilitated by guanine nucleotide exchange factors (GEFs) [14,
15]. Activated, GTP-bound Rabs engage effector molecules such as
tethering complexes [16], motor proteins and motor adaptors [17],
as well as components of the vesicle fusion machinery [18] to facili-
tate tethering and docking of vesicles to their target membranes.
Rabs have also been shown to interact directly or indirectly with some
cargo molecules [19]. Rab proteins are inactivated when the bound
GTP is hydrolysed back to GDP. This will not occur spontaneously to
any significant degree as Rabs have intrinsically weak GTPase activi-
ties. Instead, inactivation by GTP hydrolysis is assisted or regulated
by GTPase activating proteins (GAPs) [14, 20].
Given the critical importance of regulating membrane traffic
which impinges on tightly regulated processes like cell proliferation
and cell migration, it is expected that Rab small GTPases’ activities
gone awry may directly or indirectly contribute to human diseases.
Several Rab genes are associated to heritable monogenic diseases.
Rab7 mutations underlie Charcot–Marie–Tooth type 2B neuropathy,
a peripheral nervous system disorder that is believed to be due, in
part, to the dysregulation of peripherin (a neuronal intermediate fil-
ament that has been shown to interact with Rab7) [21, 22]. Rab18
mutations [23] and that of a putative RabGAP TBC1D20 [24]
causes Warburg micro-syndrome, a rare autosomal recessive
genetic disorder characterized by microcephaly, defects in the
visual system and mental retardation. Mutations in Rab23, which
plays a role in the regulation of Sonic Hedgehog (Shh) signalling,
underlie another autosomal recessive disorder, Carpenter’s syn-
drome, characterized by craniosynostosis, polysyndactyly, obesity
and cardiac defects [25, 26]. Rab27, which plays a role in melano-
some transport via its effector myosin Va, has been implicated in
Griscelli syndrome type 2, a recessive disorder in which patients
exhibit pigmentation defects like partial albinism and immune defi-
ciency [27]. Mutations in Rab39B, a Golgi-localized neuronal Rab
that may play a role in synaptic maintenance, are responsible for
X-linked mental retardation [28]. In addition, Rab38 [mutated in
rat’s Ruby (red eyed dilution; R) locus and the homologous mouse
chocolate (cht) locus] has been implicated in the autosomal reces-
sive disorder Hermansky–Pudlak syndrome (HPS) that is character-
ized by pigmentation and blood clotting disorders [29]. Recently,
mutations in several HPS genes which encode components of Bio-
genesis of lysosome-related organelles complex-3 (BLOC-3), a
Rab32 and Rab 38 GEF, have also been identified. It is postulated
that the resulting defects in the biogenesis of lysosomal related
organelles, of which Rab38 is believed to play a role, gives rise to
some of the symptoms observed in HPS, including albinism and
impaired platelet function [30]. Rab mutations or problems that are
associated with aspects of Rab-mediated transport may indeed
underlie a wider spectrum of neurological [31–33] and immune
disorders [34].
As Rabs modulate membrane trafficking of growth factor recep-
tors and cell adhesion molecules, it is also conceivable that dysregu-
lation with regard to Rab-mediated endocytosis or recycling could
lead to failure to control cell proliferation, adhesion and migration. A
good number of Rabs have also been associated with human cancer
[35, 36]. Interestingly, cellular transformation and invasion are linked
largely to changes in expression levels of these Rabs, rather than
their mutations. Rab31, a member of the Rab5 subfamily, has
recently emerged as a membrane traffic modulator that has interest-
ing associations with breast carcinoma as well as glioma, and is the
focus of this review. We first take a broad overview at our current
understanding of Rabs that have been implicated in cancer (see
summary in Table 1).
Rabs in human cancer
Dysregulated expressions of multiple Rabs spanning the entire exo-
cytic and endocytic pathways have been shown in transcription
profiling analysis of various cancer tissues [35, 36]. Rab1A, which
regulates ER-Golgi transport, is elevated in tongue squamous cell car-
cinomas [37] and melanoma [38]. Rab2, which also functions in the
ER-Golgi boundary, is elevated in peripheral blood mononuclear cells
(PBMCs) of tumour bearing patients [39, 40]. Rab5 isoforms (Rab5A,
-B and -C) are key regulators of the early endocytic pathway, and are
known to profoundly influence cell motility and invasion, possibly
through the regulation of b1-integrin traffic [41, 42]. Rab5A has been
shown to be up-regulated in non-small cell lung carcinoma [43],
autonomous thyroid adenomas [44], hepatocellular carcinoma [45]
and ovarian cancer [46]. Rab5B expression is elevated in melanoma
cells [38]. Rab5C plays a role in enhancing EGF-induced invasion by
breast cancer cells [47]. The key late endosomal Rab, Rab7, has been
shown to be up-regulated in autonomous thyroid adenomas [44] and
implicated in prostate cancer progression [48], possibly through its
down-regulation of growth factor receptor signalling and its regula-
tion of the movement of lysosomes, which carry proteinases that aid
in cell motility. Rab20 is overexpressed in exocrine pancreatic carci-
noma [49], and silencing of Rab20 reduced hypoxia-induced apoptosis
[50]. Rab23 is overexpressed in a fraction of hepatocellular carci-
noma [51] and diffuse-type gastric cancer [52]. Rab27B is involved in
multiple aspects of breast cancer progression and is a prognosis
marker. It may act through its regulation of the exocytosis of vesicles
carrying Heat shock protein (HSP)-90a, which in turn activates matrix
metalloproteases that aid in invasiveness [53–55].
Members of the Rab11 subfamily (Rab11A, Rab11B, and Rab25)
are key regulators of endocytic recycling, including that of integrin,
and their dysregulation are likely to affect aspects of cell transforma-
tion and migration [56]. Rab25 [57, 58], a member of the Rab11
subfamily that is highly expressed in the epithelial cells of the gastro-
intestinal tract, lungs and kidney, has in the past few years been impli-
cated in cancers from multiple organs. These include breast [59, 60],
ovarian [59], oesophageal [61], bladder [62] as well as head and neck
squamous cell carcinoma [63]. The Rab coupling protein (RCP) or
Rab11 family interacting protein 1 (Rab11FIP1), which is a Rab25
effector, is also well known as a breast cancer promoting gene [64].
Rab25’s role in cancer is in some cases enigmatic as it could appear
to act either as a cancer and metastasis promoter or a tumour sup-
pressor, and we have previously suggested that its mode of action
may depend on the availability of its effector RCP [65].
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There are a number of other Rabs for which changed expression
levels are associated with various types of cancers, although their
mechanism of action has not yet been speculated upon. Rab32 dysre-
gulation may be involved in tumourigenesis of neuroendocrine
tumours [66]. Rab36 resides in a portion of chromosome 22q11,
which is frequently deleted either heterozygously or homozygously in
paediatric brain rhabdoid tumours [67].
Activities of Rabs in association with cancer have, in some cases,
been shown to be epigenetically modulated. For example, down-regu-
lation of Rab37 in metastatic lung cancer could be due to of promoter
hypermethylation [68]. The micro-RNA (miR)-50 inhibits autophagy
and tumour growth in colon cancer cells by suppressing, among
other genes, the expression of Rab1B [69], the latter being an impor-
tant factor in the initiation of autophagy [70]. Another miR, miR-451,
has tumour suppressor functions in human non-small cell lung can-
cer, and could act by suppressing the expression of Rab14 [71]. On
the other hand, miR-373 could be down-regulated by aberrant pro-
moter methylation in colon cancer, with a concomitant up-regulation
of its target, Rab22A [72]. miR-200b is a prognostic factor of breast
cancer [73] and glioma [74], and it targets multiple Rabs including
Rab3B, Rab18, Rab21 and Rab23.
Rab are not conventionally denoted as either oncogenes or tumour
suppressors. However, abnormal expression of Rabs could conceiv-
ably drive several aspects of cellular transformation, particularly mito-
genic signalling and cell migration/invasion. Multiple endocytic Rabs
influence trafficking and signalling of cell surface growth factor recep-
tors. Impaired or altered Rab regulation of the endocytic itineraries of
these receptors could lead to impairment in receptor recycling or deg-
radation, thus promoting mitogenic signalling that pre-disposes cells
to oncogenic transformation [35, 75]. On the other hand, Rab-medi-
ated endocytosis and recycling is linked to cell migration and
invasion. Rab8, for example, regulates exocytosis of MT1-matrix
metalloproteinase (MT1-MMP), a key metastatic factor, to invasive
structures [76]. Rab25 appears to promote invasive migration in a
3-dimensional matrix by associating with and mediating the recycling
of a5b1 integrin and the epidermal growth factor receptor (EGFR),
likely acting through RCP [77–79]. In the next section, we outline
how Rab31 has been implicated in human cancers, and in the section
after postulate the underlying mechanisms based on recent findings.
Rab31 and findings implicating Rab31
in human cancers
Rab31 was first cloned from human melanocytes and named Rab22b
based on its close homology with Rab22 [80], but was also named
Rab31 when subsequently cloned from human platelets [81]. Rat
(rRab22b) [82] and mouse orthologues [83] were also subsequently
reported. Structurally, Rab31 is homologous to Rab5 and is grouped
Table 1 A summary of studies implicating Rabs in cancer
Rab Known physiological role Implication in cancer References
Rab1A ER-Golgi transport, autophagy Elevated in tongue squamous cell carcinomas and melanoma [37,38]
Rab2 ER-Golgi transport Elevated in peripheral blood mononuclear cells (PBMCs) of tumour
bearing patients
[39,40]
Rab5A Endocytosis Elevated in non-small cell lung carcinoma, autonomous thyroid
adenomas, hepatocellular carcinoma and ovarian cancer
[43–46]
Rab5B Endocytosis Elevated in melanoma cells [38]
Rab5C Endocytosis A role in enhancing EGF-induced invasion by breast cancer cells [47]
Rab7 Endo-lysosomal transport Elevated in autonomous thyroid adenomas, associated with prostate
cancer progression
[44, 48]
Rab8 Polarized exocytosis Regulates exocytosis of MT1-matrix metalloproteinase [76]
Rab20 Endocytosis/phagocytosis Elevated in pancreatic carcinoma [49]
Rab23 Modulation of Sonic hedgehog signalling Elevated in hepatocellular carcinoma and diffuse-type gastric cancer [51,52]
Rab25 Endosomal recycling Associated with various aspects of breast, ovarian, oesophageal, and
bladder cancers, as well as head and neck squamous cell carcinoma
[59–63]
Rab27B Regulated secretion/exocytosis Marker for breast cancer progression, invasiveness and metastasis [53–55]
Rab31 EGFR endosomal trafficking, M6PR
trafficking from TGN to late endosome
Elevated in breast cancer and influences breast cancer, cervical
cancer and glioblastoma progression
[93–99]
Rab32 Melanosome transport, mitochondrial
dynamics, autophagy
Tumourigenesis of neuroendocrine tumours [66]
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under the Rab5 subfamily [84, 85]. Larocca and colleagues first
showed that Rab31 transcripts are enriched in brain oligodendro-
cytes, and demonstrated by video microscopy that Rab31 promi-
nently labels tubulovesicular carrier structures originating from the
trans-Golgi [82], and that Rab31 regulates transport of the cation-
dependent mannose 6-phosphate receptor (CD-M6PR) from the Golgi
to the endosome [86]. The authors also showed that Rab31 interacts
with the Lowe oculocerebrorenal syndrome protein OCRL-1 (an
Inositol polyphosphate 5-phosphatase) and that this interaction is
required for trans-Golgi network (TGN) organization and transport
carrier formation [87].
We have developed Rab31 antibodies that supported an enrich-
ment of Rab31 protein in brain tissues and a functional role for
Rab31 at the TGN [83, 88]. In addition, our findings also suggested
that Rab31 has a role in regulating early endosome-late endosome
transport, particularly of the epidermal growth factor receptor (EGFR)
[88]. Other than M6PR and EGFR, Rab31 has also recently been
shown to bind the signalling adaptor protein, phosphotyrosine inter-
action, pleckstrin homology (PH) domain, and leucine zipper-contain-
ing protein (APPL) 2 [89]. Two proteins GAPex-5 [90] and Rin3 [91],
have been identified as GEFs for Rab31, and one of its confirmed
effectors is early endosome antigen 1 (EEA1), which it shares with
Rab5 and Rab22.
Several expression profiling analyses have implicated Rab31 in
human cancers. A Serial Analysis of Gene Expression (SAGE) profiling
found Rab31 to be among 11 genes that are robustly overexpressed
in samples of Oestrogen Receptor a (ERa) positive breast carcinomas
[92]. ERa is a transcription factor that is activated by oestrogens
such as oestradiol, and regulates the transcription of target genes by
binding to the oestrogen response element (ERE) upstream of the tar-
get genes. Rab31 transcripts were also found to be elevated in breast
cancer cells expressing the urokinase-type tissue plasminogen activa-
tor (uPA)-receptor splice variant uPAR-del4/5 [93–95], and high
Rab31 levels were significantly associated with distant metastasis-
free survival and overall survival [96]. An analysis in advanced ovar-
ian cancer samples did not, however, reveal any significant associa-
tion with overall or progression-free survival [97]. Rab31 is also
among the genes that associate with tumour progression in centroso-
mal protein transforming acidic coiled coil (TACC) 3 overexpressing
HeLa cells as a model of cervical cancer [98].
Other than breast cancer, Rab31 is also identified as one of the
cohort (race)-dependent associations with glioblastoma survival [99].
Meta-analysis of microarray studies using Bayesian network analysis
also found Rab31 to be among 10 genes that are most influential in
the development of glioblastoma multiforme [100].
Mechanisms underlying Rab31’s role
in cancer
Several recent findings have helped to shed light on the possible
underlying molecular pathways and mechanisms linking Rab31 to
cancer. These are outlined and discussed below, headed by key ques-
tions pertaining to Rab31’s expression and pathophysiological roles.
Why are Rab31 levels elevated in cancer cells?
Rab31 levels are elevated in breast cancer cells, and recent findings
offer two explanations for the phenomenon. One possibility is
explained by a recent discovery that Rab31 transcripts are targets of
HuR [101], an mRNA-binding and stabilizing protein of the ELAV-Hu
family [102] which could thus stabilize Rab31 transcripts, resulting in
their elevated levels (Fig. 1A). HuR itself is notably overexpressed in
breast cancer tissues and has prognostic value [103, 104]. Another
possibility is related to the observation that Rab31 is selectively ele-
vated in ERa-positive breast cancer samples [92]. A new key finding
in this regard is that the Rab31 promoter region has an ER responsive
element [105], and could be thus regulated or deregulated in breast
cancer cells by trans factors associating with the element. One such
factor turned out to be mucin-1 (MUC1), an oncogenic glycoprotein
that has been shown to be expressed in a large fraction of breast can-
cer samples [106].
MUC1 is a heterodimeric transmembrane protein consisting of
MUC1-N (which harbours mucin-like repeats) and MUC1-C, which
spans the cell membrane [107]. MUC1-C could be internalized by
clathrin-based endocytosis [108] and imported into the nucleus
[109], where it stabilizes and activates ERa [110]. Jin and colleagues
demonstrated that MUC1-C forms a complex with ERa, and could
activate Rab31 transcription in an oestradiol-dependent manner
(Fig. 1B). Up-regulated Rab31 could in turn elevate MUC1-C levels,
probably by reducing its lysosomal degradation through an as-yet-
undefined mechanism (Fig. 1C). Rab31 expression in MCF10A cells
could promote the formation of anchorage-independent cytospheric
structures (mammospheres) in a MUC1-C-dependent manner [105].
MUC1-C and Rab31 therefore appear to form an auto-inductive loop
that results in sustained over-expression of MUC1-C in breast cancer
cells. Such an auto-inductive regulatory loop has also been previ-
ously reported between MUC1-C and the Signal transducer and acti-
vator of transcription 3 (STAT3), which is also a promoter of
malignancy [111].
Is Rab31 a driver in cancer, and if so, how?
Interestingly, when Rab31 is overexpressed in breast cancer cell
lines, it enhanced proliferation and diminished cell adhesion towards
several extracellular matrix (ECM) components, as well as attenuated
cell invasion through Matrigel [112]. When breast cancer cells moder-
ately overexpressing Rab31 were xenografted onto nude mice, these
exhibited significantly reduced lung metastasis compared to control
cells. In invasive tumour lines at least, high levels of Rab31 appear
therefore to switch these cells from an invasive to a more proliferative
phenotype [112].
Could any of the factors that help elevate Rab31 levels described
above attest to Rab31’s oncogenic potential? Other than Rab31, HuR
also stabilizes the transcript of uPA and its receptor (uPAR) [113].
uPA, localized by uPAR to the plasma membrane, cleaves plasmino-
gen to give plasmin, which in turn cleaves and activates matrix metal-
loproteases (MMPs) that aid in degradation of ECM components.
uPAR is elevated during inflammation and ECM remodelling, and is
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usually associated with poor cancer prognosis [114]. uPAR could
also activate a variety of intracellular signalling pathways such as the
mitogen activated protein kinase (MAPK) pathway and the phosphati-
dylinositol 3-kinase (PI3K)-Akt pathway [115] through the engage-
ment of co-receptors, such as integrins [116]. A splice variant of
uPAR, uPAR-del4/5, which is unable to bind uPA, is a known prog-
nostic marker for breast cancer [94, 96, 113] although phenotypi-
cally, in vitro, cells overexpressing this variant appear to have
reduced invasive properties [95, 117], much like that observed for
Rab31 [112]. While Rab31 transcripts have also been found in cancer
cells with the uPAR splice variant, and both are stabilized by HuR, it is
unclear if the two have a causal or functional relationship. An interest-
ing connection with Rab31 in this regard is that uPAR interacts with
CI-M6PR [118, 119], whose TGN-endosome transport is regulated by
Rab31 [86, 87]. The interaction of uPAR with CI-M6PR may regulate
the movement of uPAR to endosomes for degradation and thus mod-
ulate the levels of uPAR on the cell surface [118] (Fig. 1D). How this
uPAR-CI-M6PR connection might relate to Rab31’s role in cancer is
yet unclear. It is, however, conceivable that Rab31 may modulate
uPAR’s activity in signalling as well as ECM modulation, via its regula-
tion of M6PR trafficking dynamics, thus impacting on tumourigenesis
and invasion.
Notably, the other modulator of Rab31 expression, MUC1-C, is a
multifunctional oncoprotein [107]. MUC1-C overexpression in fibro-
blast is sufficient to induce anchorage-independent growth and
tumour formation in nude mice [120]. In the nucleus, MUC1-C acti-
vates the Wnt/b-catenin [121], STAT3 [111] and NF-jB [122]- based
transcription, all of which have been associated with tumourigenesis.
At the plasma membrane, MUC1-C interacts with EGFR [123–125]
and perhaps other members of the ErbB family to activate the MAPK
and PI3K-Akt pathways. Furthermore, MUC1 could promote auto-
phagy and survival responses of cancer cells to nutrient deprivation
[126]. It was also recently shown to stabilize and activate hypoxia-
inducible factor-1a (HIF-1a) to regulate hypoxic response in pancre-
atic cancer cells [127]. In view of the oncogenic potency of MUC1, it
does appear that if Rab31 could effectively elevate and sustain func-
tional levels of MUC1-C, it could help drive oncogenesis.
Rab31’s modulation of EGFR trafficking –
could it be tumour suppressive?
A twist to the general plot above came about from our findings that
Rab31 directly modulates EGFR trafficking and possibly its signalling
Fig. 1 Rab31 and the interactions implicated in its role in cancer. (A) HuR stabilizes transcripts including that of Rab31 and uPAR. (B) Transcription
of Rab31 is regulated by an ER responsive element. MUC1-C stabilizes and activates ERa, which in turn activates Rab31 transcription in an estra-
diol-dependent manner. (C) Rab31 inhibits the lysosomal degradation of MUC1-C, via an as-yet-undefined mechanism, thus elevating MUC1-C lev-
els. (D) Rab31 regulates the movement of M6PR from the TGN to endosomes. M6PR, in turn, interacts with uPAR and may be responsible for its
movement to endosomes for degradation. (E) Rab31 participates in the trafficking of ligand-bound EGFR from early to late endosomes, thus enhanc-
ing the rate of degradation of ligand-bound EGFR. (F) MUC1-C is phosphorylated by ligand-bound EGFR, leading to enhanced interaction with down-
stream signalling components. In turn, MUC1-C inhibits the ubiquitination of EGFR, thus potentiating its signalling. Dashed lines represent
movement of proteins. Solid arrows represent activating mechanisms of action; solid blocked arrows represent inhibiting mechanisms of action.
TGN, trans-Golgi network; EE, early endosome; LE/MVB, late endosome/multivesicular body; PM, Plasma membrane.
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[88, 128]. A hint that Rab31 may regulate EGFR trafficking first came
from two earlier reports, the first from Stahl’s laboratory which
showed that GAPex-5, then newly identified as a Rab5 GEF, modu-
lates EGFR ubiquitination, trafficking and degradation [129]. Another
report indicated that GAPex-5 is also a GEF for Rab31, and it regu-
lates insulin-stimulated Glut4 translocation to the plasma membrane
in adipocytes [90]. We found that silencing of Rab31 inhibited, while
overexpression enhanced, EGFR trafficking to the late endosomes
(Fig. 1E), and the former observation phenocopied the effect of
GAPex-5 silencing on EGFR trafficking. Interestingly, Rab31 is associ-
ated with EGFR in a GTP-dependent manner, and this association is
dependent upon its effector early endosome antigen 1 (EEA1) as well
as GAPex-5 (but not Rin3 [91], another Rab31 GEF) [128]. Rab31
may thus be recruited as part of an EGFR-containing membrane traf-
ficking complex to regulate its transit from the early to late endo-
somes. Overexpression of Rab31 appeared to enhance the
degradation of EGFR, and we have observed that, for A431 cells at
least, this translates to a moderate decrease in the rate of cell
proliferation [88].
On the face of it, our observations in A431 cells run counter to
what might be expected for Rab31 overexpression in breast cancer
cells. Given that Rab31 overexpression in breast cancer cell lines
increased their proliferation [112], the discrepancy may be down to
cell type differences. It may also simply be just another illustration of
the complexity associated with cancer cells and tissues, where multi-
ple factors act along with, or counter the action of one another in
intersecting pathways. The cancerous phenotype, and its different
dynamic manifestations as the cancer progresses, is thus a combina-
torial sum of many. It is difficult at the moment to gauge quantita-
tively which one of the two apparently contrasting actions of Rab31,
namely the auto-inductive loop that it is engaged with MUC1-C, or its
effect on EGFR trafficking and signalling, would be a more important
determinant of the cancer phenotype. It is conceivable though that
one important determinant in the complex equation would be the
availability and activity of its GEF GAPex-5, as well as it is yet to be
identified GAP(s). In a way reminiscent to Rab25, both the availability
of regulators and effector would be important variables in determining
if the Rab would be oncogenic, or conversely tumour suppressive
[65]. Furthermore, in breast cancer in particular, any moderating
effect of Rab31 on EGFR signalling may well be completely muted by
the fact that EGFR family receptor tyrosine kinase and their mutants
are prevalent [130], or the activation of competing recycling pathways
that will recycle endocytosed EGFR back to the surface [78].
On the other hand, one should also keep in view the complex rela-
tionship between Rab31, EGFR and MUC1-C. MUC1-C itself interacts
with EGFR and is indeed a substrate of EGFR tyrosine kinase activity
[123, 124], with the phosphorylation of MUC1-C by EGFR leading to
enhanced interactions with its downstream components [123]. Con-
versely, MUC1-C was shown to inhibit ubiquitination of ligand-bound
EGFR, thus reducing the degradation and enhancing the recycling of
EGFR to the cell surface, thus potentiating its signalling [124]
(Fig. 1F). At the moment it is unclear how elevated Rab31 levels may
affect this EGFR-MUC1 interaction, but it is conceivable that the pres-
ence of Rab31 could alter EGFR signalling in this regard. Further work
should determine if this influence is positive or negative. Given that
overexpression of Rab31 in breast cancer cell lines actually enhanced
proliferation [112], Rab31, when elevated in the presence of MUC1-C
may enhance instead of retard EGFR signalling in these cells. Another
point of contention that requires further clarification pertains to the
effect of Rab31 on MUC-1C’s expression. Jin and colleagues sur-
mised that Rab31 could have diminished MUC-1C’s lysosomal degra-
dation as the lysosome inhibitor chloroquine increased MUC1-C
levels in Rab31 silenced cells. How then does Rab31 diminish late en-
dososome-lysosome targeting of MUC1-C while increasing the trans-
port of EGFR? Answers to these and other questions await resolution
by further work.
Epilogue and future perspectives
In this brief review, we have discussed how recent findings may
explain Rab31’s elevation in cancer, and how elevated Rab31 may
influence cancer cell signalling through its effect on EGFR endosomal
traffic. To fully understand the significance of Rab31 as a prognostic
marker, we posit that assessment of the levels of its regulators such
as GAPex-5 in various cancers would be important. It is far too early
to postulate if Rab31 and its regulators would have therapeutic val-
ues. However, it is conceivable that in breast cancer cells overex-
pressing EGFR or other ErbB family members, using Rab31 to
attenuate EGFR signalling may be a potentially useful adjunct therapy
to anti-EGFR drugs. This may attenuate the selection pressure that
would lead to the development of resistance against drugs targeting
EGFR [131, 132].
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